Mitochondrial subhaplogroups and differential risk of stavudine-induced lipodystrophy in Malawian HIV/AIDS patients

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 1999-2004

  Kampira, Elizabeth ^a,b   Kumwenda, Johnstone ^b   Van Oosterhout, Joep J ^b,c   Dandara, Collet ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF MALAWI   (Malawi)

^c DIGNITAS INTERNATIONAL   (Malawi)

Author keywords

dyslipidemia; lipodystrophy; mitochondrial DNA; subhaplogroups; toxicities

Indexed keywords

MITOCHONDRIAL DNA; STAVUDINE;

ADULT; ARTICLE; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALAWI; MALE; MITOCHONDRIAL GENE; PATIENT IDENTIFICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, MITOCHONDRIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HIV; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; MITOCHONDRIA; STAVUDINE;

EID: 84889042227     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.188     Document Type: Article

References (25)

1. Cossarizza A, Mussini C, Viganò A. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? Bioessays 23(11), 1070-1080 (2001).
2. van Oosterhout JJ, Mallewa J, Kaunda S et al. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS ONE 7(7), e42029 (2012).
3. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17, S141-S148 (2003).
4. Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 109(13), 1603-1608 (2004)
5. Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in women with HIV infection (FRAM). J. Acquir. Immune Defic. Syndr. 42, 562-571 (2006).
6. Domingo P, Cabeza MC, Pruvost A et al. Relationship between HIV/highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin. Infect. Dis. 50(7), 1033-1040 (2010).
7. Domingo P, Estrada V, Lopez-Aldeger J, Vilaroya F, Martinez E. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev. 14, 112-123 (2012).
8. Han SH, Zhou J, Saghayam S et al. Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr. J. 58(6), 475-484 (2011).
9. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13(13), 1659-1667 (1999).
10. van Griensven J, De Naeyer L, Mushi T et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans. R. Soc. Trop. Med. Hyg. 101(8), 793-798 (2007).
11. Lewis W. Defective mitochondrial DNA replication and NRTIs: pathophysiological implications in AIDS cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 284(1), H1-H9 (2003).
12. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S et al. Association between HLA-B4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin. Infect. Dis. 50(4), 597-604 (2010).
13. Cordery DV, Martin A, Amin J et al. The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV. AIDS 26(18), 2337-2344 (2012).
14. De Luca A, Nasi M, Di Giambenedetto S et al. Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59(2), 113-120 (2012).
15. Hendrickson SL, Kingsley LA, Ruiz-Pesini E et al. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 51(2), 111-116 (2009).
16. Sinxadi PZ, Dave JA, Samuels DC et al. Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected black South Africans: a pilot study. AIDS Res. Hum. Retroviruses 29(7), 1031-1039 (2013).
17. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361(9359), 726-735 (2003).
18. Jaffe M. [Uber den niederschlag, welchen pikrinsaure in normalen hrn erzeugt und uber eine neue reaction des kreatinins]. Z. Physiol. Chem. 10, 391-400 (1886).
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39(2 Suppl. 1), S1-S266 (2002).
20. Ramos A, Santos C, Alvarez L, Nogués R, Aluja MP. Human mitochondrial DNA complete amplification and sequencing: a new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification. Electrophoresis 30(9), 1587-1593 (2009).
21. Ramos A, Santos C, Barbena E et al. Validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification: a revision based on the new human genome reference sequence (GRCh37). Electrophoresis 32(6-7), 782-783 (2011).
22. Menezes C, Maskew M, Sanne I, Crowther N, Raal F. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect. Dis. 11, 244 (2011).
23. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV infected adults. N. Engl. J. Med. 352, 48-62 (2005).
24. Kampira E, Kumwenda J, van Oosterhout JJ, Chaponda M, Dandara C. Pharmacogenetics research developments in Africa: a focus on Malawi. Curr. Pharmacogenomics Pers. Med. 10(1), 87-97 (2012).
25. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin. Exp. Immunol. 135(2), 273-279 (2004).